RA
IRMD icon

Royce & Associates’s iRadimed IRMD Stock Holding History

Royce & Associates’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-880
Closed -$20K – 1077
2020
Q2 		$20K Buy
880
+80
+10% +$1.72K ﹤0.01% 1115
2020
Q1 		$17K Sell
800
-131
-14% -$3.12K ﹤0.01% 1103
2019
Q4 		$22K Sell
931
-182
-16% -$4.25K ﹤0.01% 1094
2019
Q3 		$23K Buy
1,113
+451
+68% +$9.21K ﹤0.01% 1110
2019
Q2 		$14K Buy
662
+46
+7% +$1.08K ﹤0.01% 1124
2019
Q1 		$17K Buy
616
+178
+41% +$4.66K ﹤0.01% 1132
2018
Q4 		$11K Sell
438
-22
-5% -$591 ﹤0.01% 1138
2018
Q3 		$17K Buy
+460
New +$12.4K ﹤0.01% 1164
2014
Q4 		– Sell
-36,300
Closed -$254K – 1345
2014
Q3 		$254K Buy
+36,300
New +$329K ﹤0.01% 1265

Other funds holding IRMD

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
RCMC
RK Capital Management (Colorado) Denver, Colorado $324K AUM 47.52% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return

Royce & Associates's IRMD Position: Q3 2020 in Review

Royce & Associates sold out of iRadimed (IRMD) in Q3 2020, closing a stake of 880 shares — an estimated $20K sold.

Royce & Associates first reported a position in IRMD in Q3 2014 and held it in 9 quarters. The position peaked at $254K in Q3 2014. 62 funds tracked by Wall St. Rank hold IRMD as of Q3 2020.

  • Royce & Associates reported no remaining iRadimed position as of Q3 2020 after selling out during the quarter.
  • Royce & Associates sold 880 iRadimed shares in Q3 2020, an estimated $20K.
  • Royce & Associates first reported a position in iRadimed in Q3 2014 and held it in 9 quarters.
  • Royce & Associates's iRadimed position peaked at $254K in Q3 2014.
  • 62 funds tracked by Wall St. Rank held iRadimed as of Q3 2020.

Based on Royce & Associates's 13F filing for Q3 2020, filed 12 Nov 2020.